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Abstract
Introduction We performed a study to determine whether an
enrollment sequence effect noted in the PROWESS
(recombinant human activated Protein C Worldwide Evaluation
in Severe Sepsis) trial exists in the ADDRESS (Administration of
Drotrecogin Alfa [Activated] [DrotAA] in Early Stage Severe
Sepsis) trial.
Methods We evaluated prospectively defined subgroups from
two large phase 3 clinical trials: ADDRESS, which included 516
sites in 34 countries, and PROWESS, which included 164 sites
in 11 countries. ADDRESS consisted of patients with severe
sepsis at low risk of death not indicated for treatment with
DrotAA. PROWESS consisted of patients with severe sepsis
with one or more organ dysfunctions. DrotAA (24 μg/kg per
hour) or placebo was infused for 96 hours.
Results In ADDRESS and PROWESS, there was a statistically
significant interaction between the DrotAA treatment effect and
the sequence in which patients were enrolled. In both trials,
higher mortality was associated with DrotAA use in the
subgroup of patients enrolled first at study sites. Compared with
placebo, PROWESS mortality was lower with DrotAA treatment
for the second and subsequent patients enrolled, whereas in
ADDRESS, mortality remained higher for the second patient
enrolled but thereafter was lower for DrotAA-treated patients.
Comparison of patients enrolled first with subsequent patients
enrolled indicated that the characteristics of patients changed.
Subsequently enrolled patients were treated earlier, were less
likely to suffer nonserious bleeds (ADDRESS), and experienced
fewer protocol violations (PROWESS).
Conclusions Analyses suggest that an enrollment sequence
effect was present in the ADDRESS and PROWESS trials.
Analysis of this effect on outcomes suggests that it is most
apparent in patients at lower risk of death. In PROWESS, this
effect appeared to be associated with a reduction of the DrotAA
treatment effect for the first patients enrolled at each site. In
ADDRESS, this effect may have contributed to early termination
of the study. The finding of an enrollment sequence effect in two
separate trials suggests that trial designs, site selection and
training, data collection and monitoring, and statistical analysis
plans may need to be adjusted for these potentially confounding
events.
Trial Registration ADDRESS trial registration number:
NCT00568737. PROWESS was completed before trial
registration was required.
ADDRESS: Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis; APACHE: Acute Physiology and Chronic Health Evaluation; 
CI: confidence interval; DrotAA: drotrecogin alfa (activated); MOD: multiple-organ dysfunction; PROWESS: Protein C Worldwide Evaluation in 
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Introduction
The Protein C Worldwide Evaluation in Severe Sepsis
(PROWESS) study demonstrated that drotrecogin alfa (acti-
vated) (DrotAA) reduced mortality in patients with severe sep-
sis [1]. Subgroup analyses suggested heterogeneity in the
observed treatment effect for some subgroups, including
those defined by baseline Acute Physiology and Chronic
Health Evaluation (APACHE) II score, by protocol violation sta-
tus, and by the sequence of enrollment at a study site [2,3].
Within these subgroups, the observed reduction in mortality
associated with DrotAA was larger for patients with higher
APACHE II scores, with no violation of the protocol, and who
comprised the second and subsequent patients enrolled at a
study site [3]. The latter two observations suggested that a
learning curve appeared to be present within PROWESS
such that the ability to demonstrate efficacy improved with
increasing site experience with the study protocol [3].
Based on subgroup analyses of PROWESS, regulatory agen-
cies approved the use of DrotAA in patients at higher risk of
death as defined, for example, by an APACHE II score of
greater than or equal to 25 or multiple-organ dysfunction
(MOD) [4,5]. As a condition for approval, the US Food and
Drug Administration required the sponsor to conduct a rand-
omized placebo-controlled trial of DrotAA in the nonindicated
population of severe sepsis patients at lower risk of death (the
Administration of Drotrecogin Alfa [Activated] in Early Stage
Severe Sepsis [ADDRESS] study) [6,7]. Based on the esti-
mated placebo mortality rate in this lower-severity population,
the ADDRESS study planned to enroll approximately 11,400
severe sepsis patients at 1,000 investigative sites in 35 coun-
tries. The ADDRESS study was prematurely terminated at the
recommendation of the safety monitoring board because of a
low likelihood of meeting the prospectively defined objective
of demonstrating a significant reduction in the risk of 28-day
all-cause mortality with DrotAA [7].
As a potential learning curve was present in the PROWESS
trial and because the ADDRESS trial would require approxi-
mately 1,000 investigative sites, many of which were without
prior clinical trial experience, prospectively defined analyses
were included in the ADDRESS statistical analysis plan to
assess the influence of any learning curve on the observed
outcomes. We report the results of these analyses and addi-
tional exploratory analyses o f  b o t h  t h e  P R O W E S S  a n d
ADDRESS databases. We discuss the results of these analy-
ses in the context of their implication on the design and con-
duct of future clinical trials in patients with severe sepsis.
Materials and methods
Both PROWESS and ADDRESS were randomized double-
blind placebo-controlled studies evaluating the efficacy (28-
day mortality) of DrotAA (Xigris®; Eli Lilly and Company, Indi-
anapolis, IN, USA) given as an intravenous infusion (24 μg/kg
per hour) for 96 hours in patients with severe sepsis. Both
studies were approved by the ethics committee of each indi-
vidual participating center, and written informed consent was
obtained from each patient or next of kin. In PROWESS,
patients were at a greater risk of death [1] than in ADDRESS
[7] (placebo 28-day mortality 30.8% versus 17.0%, respec-
tively). For ADDRESS, the study enrolled patients with severe
sepsis not indicated for treatment with DrotAA under the appli-
cable label in the country in which the patient was enrolled.
Severe sepsis was defined as the presence of a known or sus-
pected infection and at least one sepsis-induced organ dys-
function. The population indicated for DrotAA varied from
country to country but was generally defined as patients with
severe sepsis with MOD and/or an APACHE II score of
greater than or equal to 25. Randomization was stratified by
site and within site by heparin use.
Statistical analyses
In the PROWESS study, the prospectively defined analysis to
assess the influence of site enrollment on the observed treat-
ment effect was an analysis of treatment effects that potentially
differed across subgroup strata (using Breslow-Day tests).
Potential interactions were identified for subgroups defined by
presence versus absence of a significant protocol violation (P
= 0.07), original versus amended protocol (P = 0.08), and
APACHE II quartile at baseline (P = 0.09). Further examination
of these interactions led to post hoc analyses of within-site
sequence effects, as previously described [3]. Based on the
post hoc significance of an interaction related to sequence,
ADDRESS included a prospectively defined analysis to
assess the influence of site enrollment on the observed treat-
ment effect which was an analysis of 28-day mortality in the
subgroups of first patients enrolled at each investigative site
compared with the second and subsequent patients enrolled
at each site (using Breslow-Day tests). The treatment effect
was further assessed by analysis of mortality by the number of
patients (1 to 4, 5 to 8, 9 to 12, and more than 12 patients)
enrolled per site. Chi-square tests were used to compare mor-
tality rates between treated and placebo patients.
Results
At the time of termination, 2,640 patients had been enrolled in
the ADDRESS study at 516 centers in 34 countries. Mortality
data at day 28 were available for 2,613 patients (placebo, n =
1,297; DrotAA, n = 1,316). There was no statistical difference
between the placebo and DrotAA groups in 28-day all-cause
mortality (placebo, 17.0%; DrotAA, 18.5%; P = 0.34) (Table
1). Based on a prospectively defined analysis, there was a sig-
nificant treatment-by-sequence of enrollment interaction for
the first patient enrolled at each site compared with all subse-
quently enrolled patients at that site (P = 0.04). Mortality at 28
days was higher for DrotAA patients compared with placebo
patients in the subgroup of patients who comprised the first
patients enrolled at each study site (22.3% versus 14.5%).
Mortality rates were similar between treatment groups for the
second and subsequent patients enrolled at each study site.Available online http://ccforum.com/content/12/5/R117
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Similar to what had previously been reported for PROWESS
[3], treatment effect assessed by enrollment sequence
grouped by block size (four patients per block) is listed in
Table 2. In ADDRESS, mortality was higher for DrotAA
patients compared with placebo in the first block, similar to
placebo in the second block, and lower than placebo in the
third and subsequent blocks. The median number of patients
enrolled per site was eight. A treatment-by-enrollment
sequence was observed at both small (≤8 patients) and high
(>8 patients) enrolling sites (data not shown).
In PROWESS, a statistically significant treatment-by-enroll-
ment interaction was also observed (P = 0.007) (Table 2).
However, in PROWESS, mortality was lower for DrotAA
patients compared with placebo in all randomization blocks,
although the difference was larger in the second and subse-
quent blocks of patients. The relative risk associated with
DrotAA was similar between ADDRESS and PROWESS for
patients enrolled in the third and subsequent blocks. Addition-
ally, patients enrolled in the third and subsequent blocks rep-
resented 45.5% of all PROWESS patients (n = 769/1,690)
and only 21.4% of ADDRESS patients (n = 558/2,613).
In PROWESS, randomization was stratified only by site, result-
ing in a uniform block size of four at each site. However, in
ADDRESS, randomization was also stratified by baseline
heparin use, so there was no uniform block size for randomiza-
tion, thus the first four patients (in theory) could have all
received DrotAA or all placebo or some other combination.
Thus, further exploratory analyses were performed by sub-
groups in which the first through fourth patients enrolled at
each site were excluded from the analysis. In ADDRESS (Fig-
ure 1a), 28-day mortality was lower for DrotAA patients com-
pared with placebo patients in the subgroup of patients
excluding the first two patients enrolled at a site (16.6% ver-
sus 18.4%). These data are similar to those in PROWESS in
which higher mortality was observed for DrotAA patients com-
pared with placebo patients who comprised the first enrolled
Table 1
Twenty-eight-day mortality for all patients enrolled in ADDRESS and for sequence subgroups
Drotrecogin alfa (activated) Placebo Relative risk 95% CI Breslow-Day P value
Number Died (percentage) Number Died (percentage)
All randomly assigned patients 1,316 243 (18.47) 1,297 221 (17.04) 1.08 0.92, 1.28
Patient classification 0.04
First patient only 260 58 (22.31) 249 36 (14.46) 1.54 1.06, 2.25
Excluding first patient 1,056 185 (17.52) 1,048 185 (17.65) 0.99 0.82, 1.19
ADDRESS, ADministration of DRotrecogin alfa (activated) in Early Stage Severe Sepsis; CI, confidence interval.
Table 2
Mortality rates and relative risks for drotrecogin alfa (activated) by enrollment sequence within a site: ADDRESS and PROWESS
ADDRESS PROWESS
Enrollment 
sequence within 
a site
Placebo DrotAA Placebo DrotAA
Number Mortality 
percentage
Number Mortality 
percentage
RR (95% CI) Number Mortality 
percentage
Number Mortality 
percentage
RR (95% CI)
1st to 4th 
patients
727 15.5% 741 20.1% 1.29 (1.04, 
1.62)
279 31.5% 280 28.6% 0.91 (0.71, 
1.17)
5th to 8th 
patients
303 17.5% 284 17.3% 0.99 (0.69, 
1.40)
179 29.6% 183 24.4% 0.81 (0.58, 
1.14)
9th to 12th 
patients
132 19.7% 142 16.2% 0.82 (0.49, 
1.37)
128 25.8% 121 20.7% 0.80 (0.51, 
1.26)
>12th patients 135 21.5% 149 14.8% 0.69 (0.42, 
1.14)
254 33.5% 266 22.9% 0.69 (0.52, 
0.91)
ADDRESS, ADministration of DRotrecogin alfa (activated) in Early Stage Severe Sepsis; CI, confidence interval; DrotAA, drotrecogin alfa 
(activated); PROWESS, Protein C Worldwide Evaluation in Severe Sepsis; RR, relative risk.Critical Care    Vol 12 No 5    Laterre et al.
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patients at each site (n = 164 patients, 26.2% versus 20.0%).
However, this 'first patient' effect was relatively small com-
pared with the remaining patients in the study (Figure 1b).
To explore interactions between mortality and the sequence of
patient enrollment, ADDRESS patients were divided into sub-
groups comprising the first two enrolled patients at each site
(≤2 subgroup, n = 904) and those comprising the third and
subsequently enrolled patients (≥3 subgroup, n = 1,709). For
patients in the ≤2 subgroup, 28-day mortality rates were
21.9% and 15.8% for DrotAA and placebo patients, respec-
tively. In the ≥3 subgroup, 28-day mortality rates were 16.6%
and 18.4% for DrotAA and placebo patients, respectively.
Baseline characteristics for these subpopulations are shown
in Table 3. Compared with patients in the ≤2 subgroup,
patients in the ≥3 subgroup site tended to be enrolled in coun-
tries other than the US and Canada (indicating that 'patients
per site' rates were generally lower in the US and Canada
compared with the rest of the world), had lower acute physiol-
ogy scores, and were more likely to have chronic health points,
to have undergone recent surgery, and to have received pro-
phylactic-dose heparin. These patients were also less likely to
have community-acquired infections. Additionally, time from
documented first organ dysfunction to start of study drug
administration was shorter for third and subsequent patients
enrolled at a site compared with the first two patients enrolled.
In PROWESS, approximately 90% of patients started study
drug within 24 hours [1], whereas in ADDRESS this was only
50%.
The frequencies of serious bleeding events and any bleeding
events in ADDRESS were also compared between the ≤2 and
≥3 subgroups (Table 4). The frequencies of serious bleeding
events were similar between the ≤2 and ≥3 subgroups for
both DrotAA and placebo patients. For DrotAA patients, a sta-
tistically significantly higher percentage of patients in the ≤2
subgroup experienced 'any bleeding' and 'any bleeding during
the infusion' compared with DrotAA patients in the ≥3 sub-
group. A lower percentage of DrotAA patients in the ≥3 sub-
group experienced a transfusion compared with patients in the
≤2 subgroup (P = 0.13). A similar pattern for bleeding events
and transfusions was observed in placebo patients, but the dif-
ferences between the ≤2 and ≥3 subgroups did not reach sta-
tistical significance.
Figure 1
Twenty-eight-day mortality in all randomly assigned patients in ADDRESS (a) and PROWESS (b) with no patients removed from the analysis and  also with the first through fourth patients enrolled at each site removed Twenty-eight-day mortality in all randomly assigned patients in ADDRESS (a) and PROWESS (b) with no patients removed from the analysis and 
also with the first through fourth patients enrolled at each site removed. Note: 0 represents the results for the entire population, and 1 through 4 cor-
respond to the analysis with the first through fourth patients from each site removed. ADDRESS, ADministration of DRotrecogin alfa (activated) in 
Early Stage Severe Sepsis; DrotAA, drotrecogin alfa (activated); PBO, placebo; PROWESS, Protein C Worldwide Evaluation in Severe Sepsis.Available online http://ccforum.com/content/12/5/R117
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Table 3
Baseline characteristics for ADDRESS sequence subgroups
Variable First 2 patients (n = 916) 3rd and subsequent patients (n = 1,724) P value
Male, number (percentage) 517 (56.4%) 999 (57.9%) 0.46
Age in years, mean ± SD 58.3 ± 16.8 58.9 ± 16.6 0.36
Region, number (percentage) <0.001
Europe 265 (28.9%) 581 (33.7%)
US and Canada 480 (52.4%) 681 (39.5%)
Other countries 171 (18.7% 462 (26.8%)
Racial origin, number (percentage) 0.001
African descent 67 (7.3%) 98 (5.7%)
Caucasian 694 (75.8%) 1,221 (70.8%)
Hispanic 57 (6.2%) 144 (8.4%)
Asian 62 (6.7%) 168 (9.7%)
Other 36 (3.9%) 93 (5.4%)
Number of organ failures, mean ± SD 1.5 ± 0.7 1.4 ± 0.7 0.19
APACHE II score, mean ± SD 18.3 ± 5.7 18.1 ± 5.9 0.22
Acute physiology score, mean ± SD 14.1 ± 5.4 13.7 ± 5.4 0.07
Number of patients with chronic health points (percentage) 221 (24.1%) 476 (27.6%) 0.08
Recent surgery, number (percentage) 321 (35.0%) 681 (39.5%) 0.06
Time from first organ failure to start of study drug in hours, 
mean ± SD
24.1 ± 13.6 21.8 ± 13.7 <0.001
Community-acquired infection, number (percentage) 688 (75.1%) 1,235 (71.6%) 0.06
Heparin use at baseline, number (percentage) 504 (55.0%) 1,047 (60.7%) 0.005
Frequencies were analyzed using a chi-square test. Means were analyzed using a type III sum squares analysis of variance on the ranks. 
ADDRESS, ADministration of DRotrecogin alfa (activated) in Early Stage Severe Sepsis; APACHE, Acute Physiology and Chronic Health 
Evaluation; SD, standard deviation.
Table 4
Summary of adverse events by sequence of enrollment (ADDRESS)
Variable Drotrecogin alfa (activated) Placebo
≤2nd patient (n = 459) ≥3rd patient (n = 858) P value ≤2nd patient (n = 422) ≥3rd patient (n = 851) P value
Patients with ≥1 SBE 16 (5.5%) 35 (4.1%) 0.60 11 (2.5%) 17 (2.0%) 0.57
Patients with ≥1 SBE 
during infusion
9 (2.0%) 22 (2.6%) 0.49 6 (1.4%) 9 (1.1%) 0.63
Patients with ≥1 BE 61 (13.3%) 82 (9.6%) 0.04 33 (7.5%) 50 (5.9%) 0.27
Patients with ≥1 of any 
BE during infusion
53 (11.5%) 69 (8.0%) 0.04 28 (6.3%) 41 (4.8%) 0.25
Patients requiring any 
blood transfusion
38 (8.3%) 52 (6.1%) 0.13 19 (4.3%) 25 (2.9%) 0.20
Patients with ≥1 BE and 
who did not survive
28 (6.1%) 29 (3.4%) 0.02 7 (1.7%) 16 (1.9%) 0.68
'≤2nd patient' refers to the first two patients enrolled. '≥3rd patient' refers to the third and subsequent patients enrolled. Frequencies were 
analyzed using a chi-square test. ADDRESS, ADministration of DRotrecogin alfa (activated) in Early Stage Severe Sepsis; BE, bleeding event 
reported as an adverse event; SBE, bleeding event reported as a serious adverse event.Critical Care    Vol 12 No 5    Laterre et al.
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Mortality for patients experiencing any bleeding event in
ADDRESS was higher than for patients not experiencing a
bleeding complication, irrespective of treatment group. For
placebo patients, 28-day mortality rates were 27.7% (95%
confidence interval [CI] 18.1% to 37.3%) and 16.3% (95% CI
14.2% to 18.4%) for patients who did and did not experience
a bleeding complication, respectively. For DrotAA, 28-day
mortality rates were 40.1% (95% CI 32.1% to 48.2%) and
15.8% (95% CI 13.8% to 17.9%) for patients who did and did
not experience a bleeding complication, respectively. The per-
centage of patients who experienced a bleeding event and
subsequently died was significantly less for DrotAA patients in
the ≥3 subgroup compared with the 2 subgroup (3.4% versus
6.1%; P = 0.02), whereas there was no difference between
subgroups in placebo patients (1.9% versus 1.7%; P = 0.68)
(Table 4). An analysis of baseline characteristics for patients
who experienced any bleeding event indicated that these
patients were more severely ill compared with patients who
did not have a bleeding event (data not shown). Consequently,
the presence of a bleeding complication could have been a
marker for higher disease severity; hence, these patients might
have been expected to have higher mortality.
Sequence effect in selected subgroups
As statistically significant treatment-by-sequence of enroll-
ment interactions were present in both ADDRESS and
PROWESS, selected subgroups from both studies were also
examined. Figure 2 displays 28-day mortality for patients with
MOD enrolled in ADDRESS or PROWESS for subgroups in
which the first through fourth patients enrolled at each site
were excluded from the analysis. A treatment-by-sequence of
enrollment interaction was present in the ADDRESS (P  =
0.006) but not in the PROWESS MOD subpopulations. A
similar analysis was performed for the APACHE II score ≥25
subgroup (Figure 3). As with the MOD subgroup in PROW-
ESS, no treatment-by-sequence of enrollment interaction was
present in PROWESS patients with APACHE II scores ≥25.
However, in the ADDRESS subgroup, we observed a signifi-
cant interaction (P = 0.01) that appeared to result from an
increase in the mortality rate for placebo patients, despite the
absence of an increase in the APACHE II score as sites
enrolled more patients. There was not a parallel increase in
mortality for the DrotAA patients.
Similar analyses were conducted for subpopulations defined
as single-organ dysfunction surgical patients (Figure 4) and
Figure 2
Twenty-eight-day mortality in all randomly assigned patients with multiple organ dysfunction in ADDRESS (a) and PROWESS (b) with no patients  removed from the analysis and also with the first through fourth patients enrolled at each site removed Twenty-eight-day mortality in all randomly assigned patients with multiple organ dysfunction in ADDRESS (a) and PROWESS (b) with no patients 
removed from the analysis and also with the first through fourth patients enrolled at each site removed. Note: 0 represents the results for the entire 
population, and 1 through 4 correspond to the analysis with the first through fourth patients from each site removed. ADDRESS, ADministration of 
DRotrecogin alfa (activated) in Early Stage Severe Sepsis; DrotAA, drotrecogin alfa (activated); MOD, multiple organ dysfunction; PBO, placebo; 
PROWESS, Protein C Worldwide Evaluation in Severe Sepsis.Available online http://ccforum.com/content/12/5/R117
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single-organ dysfunction medical patients (Figure 5). For sin-
gle-organ dysfunction surgical patients, no treatment-by-
sequence of enrollment interaction was present in either the
ADDRESS or the PROWESS study. However, mortality was
higher for DrotAA patients compared with placebo patients in
ADDRESS (20.7% versus 14.1%, n = 636) and was similar to
placebo patients in PROWESS (Figure 4). In ADDRESS, an
analysis by type of single-organ dysfunction in surgical
patients suggested that the higher mortality observed in
DrotAA compared with placebo patients was due to those
patients with isolated respiratory failure (21.1% versus 10.4%;
P  < 0.05). Strong trends for treatment interactions were
present in the single-organ dysfunction medical patients in
both the ADDRESS (P = 0.051) and PROWESS (P = 0.058)
trials (Figure 5). As the above results suggested that any treat-
ment-by-sequence of enrollment interaction might be most
apparent in lower-risk patients, the entire ADDRESS popula-
tion was compared with the lower-risk population in PROW-
ESS as defined by an APACHE II score of less than 25 (Figure
6). A treatment-by-sequence of enrollment interaction was
present in ADDRESS (P = 0.04) and only a trend in PROW-
ESS (P = 0.11).
Discussion
In both PROWESS and ADDRESS, there appeared to be an
influence of enrollment sequence within a site on the observed
treatment effect with DrotAA. Analyses of the ADDRESS and
PROWESS studies suggest that the enrollment sequence
effect or 'learning curve' may be largely confined to the popu-
lations with a lower risk of death and may relate to difficulties
in diagnosis, timely diagnosis, or a situation in which small
absolute reductions in mortality may not overcome the compli-
cations of therapy.
In ADDRESS, as in the PROWESS study, there was a statis-
tically significant interaction between the observed treatment
effect associated with DrotAA and the sequence in which
patients were enrolled at study sites. In both trials, greater
mortality was found with DrotAA use within the subgroup that
comprised the first patients enrolled at study sites. In PROW-
ESS, mortality was lower with DrotAA treatment for the sec-
Figure 3
Twenty-eight-day mortality in all randomly assigned patients with an APACHE II score of greater than or equal to 25 in ADDRESS (a) and PROW- ESS (b) with no patients removed from the analysis and also with the first through fourth patients enrolled at each site removed Twenty-eight-day mortality in all randomly assigned patients with an APACHE II score of greater than or equal to 25 in ADDRESS (a) and PROW-
ESS (b) with no patients removed from the analysis and also with the first through fourth patients enrolled at each site removed. Note: 0 represents 
the results for the entire population, and 1 through 4 correspond to the analysis with the first through fourth patients from each site removed. 
ADDRESS, ADministration of DRotrecogin alfa (activated) in Early Stage Severe Sepsis; APACHE, Acute Physiology and Chronic Health Evalua-
tion; DrotAA, drotrecogin alfa (activated); PBO, placebo; PROWESS, Protein C Worldwide Evaluation in Severe Sepsis.Critical Care    Vol 12 No 5    Laterre et al.
Page 8 of 13
(page number not for citation purposes)
Figure 4
Twenty-eight-day mortality in all randomly assigned surgical patients with single organ dysfunction in ADDRESS (a) and PROWESS (b) with no  patients removed from the analysis and also with the first through fourth patients enrolled at each site removed Twenty-eight-day mortality in all randomly assigned surgical patients with single organ dysfunction in ADDRESS (a) and PROWESS (b) with no 
patients removed from the analysis and also with the first through fourth patients enrolled at each site removed. Note: 0 represents the results for the 
entire population, and 1 through 4 correspond to the analysis with the first through fourth patients from each site removed. ADDRESS, ADministra-
tion of DRotrecogin alfa (activated) in Early Stage Severe Sepsis; DrotAA, drotrecogin alfa (activated); OD, organ dysfunction; PBO, placebo; 
PROWESS, Protein C Worldwide Evaluation in Severe Sepsis.Available online http://ccforum.com/content/12/5/R117
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ond and subsequent patients enrolled at a site. However, in
ADDRESS, mortality remained higher with DrotAA compared
with placebo for the second patients enrolled. Thereafter, mor-
tality was lower for DrotAA-treated patients compared with
placebo.
A comparison of baseline characteristics for patients in
ADDRESS who comprised the first two patients enrolled at a
site compared with the third and subsequent patients indi-
cated that there were changes in the characteristics of
patients enrolled in the study as the site gained experience
with the protocol. Specifically, differences were observed
between the subgroups in the racial origin of patients, acute
physiology scores, percentage of patients with chronic health
points, surgical status, and heparin use. The mean time from
the onset of first organ failure to treatment with study drug
decreased from 24.1 to 21.8 hours for the first two patients
compared with subsequent patients (P  < 0.001). The
observed relative risk for DrotAA was similar between studies
for patients enrolled in the third and subsequent patient blocks
(0.82 versus 0.80 and 0.69 versus 0.69 for patients in the
third block and subsequent blocks, respectively). An analysis
of outcomes within clinically relevant subgroups suggested
that any sequence effect is contained within the population of
patients at lower risk of death. These data suggest that a
potential sequence effect was present in the ADDRESS study
as was observed in PROWESS.
An analysis of bleeding complications by sequence of enroll-
ment in ADDRESS also indicated that sites enrolled patients
at lower risk of bleeding in both the DrotAA and placebo
groups. The percentage of patients experiencing any bleeding
complications declined in both treatment groups as sites
enrolled more patients into the study. Patients in the ≥3 sub-
group who received DrotAA received fewer transfusions com-
pared with those patients in the ≤2 subgroup. In both
treatment groups, mortality was higher for patients experienc-
ing any bleeding complications compared with those who did
not have a bleeding event. As bleeding events were more com-
mon in the DrotAA groups, there were more patients in this
group compared with placebo who experienced any bleeding
event and did not survive. Patients experiencing a bleeding
event were more severely ill than those who did not experience
a bleeding event, so a direct contribution to the cause of death
could not be determined but certainly cannot be excluded.
Determining the influence of sequential changes in patient
characteristics on the outcome of ADDRESS is difficult. Previ-
Figure 5
Twenty-eight-day mortality in all randomly assigned medical patients with single organ dysfunction in ADDRESS (c) and PROWESS (d) with no  patients removed from the analysis and also with the first through fourth patients enrolled at each site removed Twenty-eight-day mortality in all randomly assigned medical patients with single organ dysfunction in ADDRESS (c) and PROWESS (d) with no 
patients removed from the analysis and also with the first through fourth patients enrolled at each site removed. Note: 0 represents the results for the 
entire population, and 1 through 4 correspond to the analysis with the first through fourth patients from each site removed. ADDRESS, ADministra-
tion of DRotrecogin alfa (activated) in Early Stage Severe Sepsis; DrotAA, drotrecogin alfa (activated); OD, organ dysfunction; PBO, placebo; 
PROWESS, Protein C Worldwide Evaluation in Severe Sepsis.Critical Care    Vol 12 No 5    Laterre et al.
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ous data have suggested that the observed treatment effect
associated with DrotAA is larger if treatment is initiated within
24 hours of first organ failure [8]. The presence of a sequence
effect in low-risk patients only may suggest the difficulty of
making the diagnosis of severe sepsis in this clinical setting.
The influence of protocol violations on outcome could not be
assessed because less than 50% of patients were monitored.
However, protocol violations reduced the observed treatment
effect in PROWESS [3]. Fewer bleeding complications and
transfusions in DrotAA patients comprising the third and sub-
sequently enrolled subgroup could have contributed to the
lower observed mortality. However, an important aspect of
these data is that the population of patients enrolled in a clini-
cal study may change as sites gain experience with a protocol
and patient identification, leading to change in the observed
treatment effect associated with an intervention as sites enroll
more patients in the study. These observations have important
implications for the design of future trials. For example, the
ongoing PROWESS shock study (a randomized placebo-con-
trolled trial of DrotAA in adults with persistent shock) is using
an academic coordinating center to approve every patient
enrolled into the study. In addition, this trial has robust source
data verification and documentation of protocol violations
which will allow for re-education if the sites demonstrate inad-
equate understanding of the protocol.
Learning curves have been described in other clinical trials
and in clinical practice. Halm and colleagues [9] performed a
literature review of studies examining the independent relation-
ship between hospital or physician volume and clinical out-
comes. They found that, overall, 71% of all studies of hospital
volume and 69% of studies of physician volume reported sta-
tistically significant associations between higher volume and
better outcomes. The strongest associations were found for
AIDS treatment and for surgery on pancreatic cancer, esopha-
geal cancer, abdominal aortic aneurysms, and pediatric car-
diac problems. However, it is not always clear what exactly is
responsible for these different outcomes.
While it is perhaps easier to explain a sequence effect in rela-
tion to surgical procedures, as well as AIDS treatments noted
earlier, there have been a number of studies investigating the
relationship between outcome and clinical experience with the
use of tissue-type plasminogen activator (tPA) in ischemic
stroke. Heuschmann and colleagues [10] found that data from
the German Stroke Registers Study Group indicated that in-
hospital mortality of ischemic stroke patients after tPA use var-
ied among hospitals with different experience in tPA treatment
in routine clinical practice. There have been additional studies
from different countries indicating that tPA should be adminis-
tered by experienced physicians in hospitals with expertise in
Figure 6
Twenty-eight-day mortality in all randomly assigned patients in ADDRESS (a) and in PROWESS (b) with an APACHE II score of less than 25, with  no patients removed from the analysis, and also with the first through fourth patients enrolled at each site removed Twenty-eight-day mortality in all randomly assigned patients in ADDRESS (a) and in PROWESS (b) with an APACHE II score of less than 25, with 
no patients removed from the analysis, and also with the first through fourth patients enrolled at each site removed. Note: 0 represents the results for 
the entire population, and 1 through 4 correspond to the analysis with the first through fourth patients from each site removed. ADDRESS, ADminis-
tration of DRotrecogin alfa (activated) in Early Stage Severe Sepsis; APACHE, Acute Physiology and Chronic Health Evaluation; DrotAA, drotrec-
ogin alfa (activated); PBO, placebo; PROWESS, Protein C Worldwide Evaluation in Severe Sepsis.Available online http://ccforum.com/content/12/5/R117
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acute stroke care and that published treatment guidelines
should be followed [11-15]. Similar to the findings associated
with following tPA treatment guidelines, adherence to the
American College of Critical Care Medicine-Pediatric
Advanced Life Support guidelines for hemodynamic support
for newborns and children in septic shock has been noted to
be associated with improved survival [16].
Data analyses based on secondary objectives in a clinical
study and post hoc exploratory analyses suffer from concerns
over the play of chance in multiple comparisons as well as
reporting bias. Primary and secondary analyses have been
reported for both the PROWESS and ADDRESS studies. The
initial report of a treatment-by-enrollment interaction in
PROWESS was considered hypothesis-generating. However,
this finding in a subsequent trial suggests that such a
sequence effect may have important implications for study
design and data interpretation. Nevertheless, such findings do
not alter the overall conclusions of these studies.
The exact cause of the 'enrollment sequence' remains uncer-
Table 5
Potential recommendations to assist in the design of future clinical trials
Recommendation Potential benefits Potential issues
More extensive inclusion and exclusion criteria that 
are more descriptive of the population to be enrolled
Less opportunity for patient variability and 
sites having to 'learn as they go'
Lower likelihood of extrapolating efficacy 
observed in the clinical trial to effectiveness in 
clinical practice
Standardize the major facets of severe sepsis 
concomitant care
Reduced variability as caring for patients 
with severe sepsis may be a more complex 
'procedure' than many commonly 
performed surgical procedures
May be questions related to the applicability of 
the study results to a more general severe 
sepsis population, in which concomitant care 
has not been standardized
Given the heterogeneity of severe sepsis patients, 
different populations of patients may require unique 
sets of inclusion and exclusion criteria (for example, 
medical patients and surgical patients).
Optimizes inclusion and exclusion criteria 
without the extra time and resources that 
would be needed to run two separate 
studies
May be issues with interpretation of data and 
powering if the treatment effect differs 
significantly between the two populations, in 
which two separate studies may be preferable
Use a clinical coordinating center to assist study 
sites in enrollment of eligible patients.
Helps to optimize protocol compliance May be questions related to the applicability of 
the study results to a more general severe 
sepsis population
Site selection should be based on having good 
clinical trial and critical care experience.
Helps to minimize variability and 
(potentially) protocol violations
May be questions related to the applicability of 
the study results to a more general severe 
sepsis population
The use of severity scoring systems in clinical trials 
may require training and validation of the training to 
ensure proper collection of severity of illness 
information.
Helps to ensure the collection of accurate 
data
Additional time and resources required
Given the potential influence of site experience on 
outcomes, randomization stratified by site should be 
considered a requirement for studies in complex 
disease states.
Helps to minimize effect of differences 
between sites and enrollment sequence 
effect
May limit ability to stratify by additional 
parameters
Planned enrollment per site should be based on the 
block size used for randomization. Expected 
enrollment per site should be at least two full blocks 
of patients.
Helps to minimize enrollment sequence 
effect
May only be able to have larger sites in the 
study, raising questions related to 
generalizability of the results
Futility stopping rules should incorporate the 
potential for learning curves to obscure a beneficial 
treatment effect in the early stages of a clinical trial.
Helps to avoid type II error May be a delay in identifying futility signals if no 
enrollment sequence effect is present
Statistical analysis plans should explore the 
potential for learning curves within the clinical trial 
dataset.
Prospectively defined analyses have 
greater weight and may help to explain 
study findings
Additional workload
Clinical studies should have a prospectively defined 
monitoring plan. Source data verification and 
documentation of protocol violations should be 
performed on the first few patients enrolled at a site 
until the site demonstrates adequate understanding 
of the protocol.
Helps to minimize protocol violations Additional time and resources requiredCritical Care    Vol 12 No 5    Laterre et al.
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tain. We have demonstrated associated changes in patient
characteristics, but it is not clear whether these or other 'unre-
corded' differences may be responsible. Changes in patient
management, particularly in relation to DrotAA administration,
could also be important, but not all of the details of patient
management were collected. Two factors that could be impor-
tant are time to treatment, which has previously been linked to
improved outcome with DrotAA treatment [17], and the fre-
quency of bleeding events. We hypothesize that the
'sequence effect' may be more apparent in populations with
lower mortality risk because the absolute mortality reduction is
anticipated to be less in this population and thus it may be
more difficult to demonstrate efficacy in this situation unless
treatment conditions are optimized. The 'enrollment sequence'
may thus have been more apparent in ADDRESS because
much of this population was at low risk.
Conclusion
Analysis of the ADDRESS and PROWESS studies suggests
that an enrollment sequence effect was present in both stud-
ies. In PROWESS, this enrollment sequence effect reduced
the observed treatment effect associated with DrotAA. In
ADDRESS, this enrollment sequence effect may have contrib-
uted to the decision to recommend early termination of the
study for futility. The finding of such an enrollment sequence
effect in two separate clinical trials in severe sepsis suggests
that trial designs, site training, data collection and monitoring,
and statistical analysis plans need to be adjusted for these
potential confounders. A list of potential recommendations to
assist in the design of future clinical trials is shown in Table 5.
Competing interests
Eli Lilly and Company provided financial support for this study.
P-FL, ARJG, J-FD, and EA have participated in trials spon-
sored by Eli Lilly and Company and/or have served as paid
consultants for Eli Lilly and Company. WLM, JJ, MDW, and
DRN are employees and stockholders of Eli Lilly and
Company.
Authors' contributions
P-FL and EA participated in the conception and design of the
study, in the development and conduct of analyses, and in the
clinical trials and data collection. WLM, JJ, and DRN partici-
pated in the conception and design of the study, in the devel-
opment and conduct of analyses, and in drafting the
manuscript. MDW participated in drafting the manuscript. J-
FD participated in the clinical trials and data collection. All
authors contributed to the analysis and interpretation of the
data and to critical review, revisions, and final approval of the
final manuscript.
Acknowledgements
We would like to acknowledge Karen Shields for her editorial assistance 
and David Sundin, who provided technical, administrative, and editorial 
services on behalf of Eli Lilly and Company in preparation of the 
manuscript.
References
1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF,
Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely
EW, Fisher CJ, Recombinant Human Activated Protein C World-
wide Evaluation in Severe Sepsis (PROWESS) Study Group: Effi-
cacy and safety of recombinant human activated protein C for
severe sepsis.  N Engl J Med 2001, 344:699-709.
2. Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut
JF, Vincent JL, Macias WL, Bernard GR, PROWESS Investigators:
Drotrecogin alfa (activated) administration across clinically
important subgroups of patients with severe sepsis.  Crit Care
Med 2003, 31:12-19.
3. Macias WL, Vallet B, Bernard GR, Vincent JL, Laterre PF, Nelson
DR, Derchak PA, Dhainaut JF: Sources of variability on the esti-
mate of treatment effect in the PROWESS trial: implications for
the design and conduct of future studies in severe sepsis.  Crit
Care Med 2004, 32:2385-2391.
4. EPARs for authorised medicinal products for human use –
Xigris   [http://www.emea.europa.eu/humandocs/Humans/EPAR/
xigris/Xigris.htm]
5. Xigris™ Drotrecogin alfa (activated) package insert   [http://
www.fda.gov/cder/foi/label/2001/droteli112101LB.pdf]
6. Drotrecogin alfa (activated) Product Approval Information –
Licensing Action   [http://www.fda.gov/cder/foi/appletter/2001/
droteli112101L.htm]
7. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL,
Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perr-
otin D, Sablotzki A, Arkins N, Utterback BG, Macias WL, Adminis-
tration of Drotrecogin alfa (activated) in Early Stage Severe Sepsis
(ADDRESS) Study Group: Drotrecogin alfa (activated) for
adults with severe sepsis and a low risk of death.  N Engl J Med
2005, 353:1332-1341.
8. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH,
Johnson G 3rd, Bernard GR, Recombinant Human Activated Pro-
tein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study
Group: Effects of drotrecogin alfa (activated) on organ dys-
function in the PROWESS trial.  Crit Care Med 2003,
31:834-840.
9. Halm EA, Lee C, Chassin MR: Is volume related to outcome in
health care? A systematic review and methodologic critique of
the literature.  Ann Intern Med 2002, 137:511-520.
10. Heuschmann PU, Berger K, Misselwitz B, Hermanek P, Leffmann
C, Adelmann M, Buecker-Nott HJ, Rother J, Neundoerfer B, Kalo-
minsky-Rabas PL, for the German Stroke Registers Study Group
and for the Competence Net Stroke: Frequency of thrombolytic
therapy in patients with acute ischemic stroke and the risk of
in-hospital mortality.  Stroke 2003, 34:1106-1113.
Key messages
￿  In the ADDRESS and PROWESS studies, a significant 
interaction between drotrecogin alfa (activated) treat-
ment effect and the sequence in which patients were 
enrolled was observed.
￿  Characteristics of patients enrolled first changed com-
pared with subsequent patients, including earlier treat-
ment and fewer protocol violations in the latter group.
￿  The enrollment sequence effect observed in two sepa-
rate trials suggests the need for analyses adjusted for 
confounding events.
￿  Future study designs in severe sepsis should include 
site selection and training, close monitoring of strict 
protocol adhesion, sufficient recruitment per site, and a 
clinical coordinating center to ensure adequate patient 
selection.Available online http://ccforum.com/content/12/5/R117
Page 13 of 13
(page number not for citation purposes)
11. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA,
Hammel JP, Qu A, Sila CA: Use of tissue-type plasminogen acti-
vator for acute ischemic stroke: the Cleveland area
experience.  JAMA 2000, 283:1151-1158.
12. Gladstone DJ, Black SE: Update on intravenous tissue plas-
minogen activator for acute stroke: from clinical trials to clini-
cal practice.  CMAJ 2001, 165:311-317.
13. Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campbell M, Mor-
genstern LB, Malkoff M, Alexandrov AV: Intravenous tissue-type
plasminogen activator therapy for ischemic stroke: Houston
experience 1996 to 2000.  Arch Neurol 2001, 58:2009-2013.
14. Graham GD: Tissue plasminogen activator for acute ischemic
stroke in clinical practice: a meta-analysis of safety data.
Stroke 2003, 34:2847-2850.
15. Szoeke CE, Parsons MW, Butcher KS, Baird TA, Mitchell PJ, Fox
SE, Davis SM: Acute stroke thrombolysis with intravenous tis-
sue plasminogen activator in an Australian tertiary hospital.
Med J Aust 2003, 178:324-328.
16. Han YY, Carcillo JA, Dragotta MA, Bills DM, Watson RS, Wester-
man ME, Orr RA: Early reversal of pediatric-neonatal septic
shock by community physicians is associated with improved
outcome.  Pediatrics 2003, 112:793-799.
17. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut
JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin
DP, Turlo MA, Janes J: Drotrecogin alfa (activated) treatment in
severe sepsis from the global open-label trial ENHANCE: fur-
ther evidence for survival and safety and implications for early
treatment.  Crit Care Med 2005, 33:2266-2277.